VRAX

Virax Biolabs Group Limited (NASDAQ:VRAX) is a biotechnology company founded in 2021 and headquartered in London, United Kingdom. The company went public in July 2022 during the height of global interest in diagnostic testing and personal protective equipment following the COVID-19 pandemic. Originally incorporated as Virax Biolabs (Cayman) Limited, the company changed its name to its current form in September 2021. Virax operates as a distributor and marketer of diagnostic test kits and medical technology products, serving healthcare providers and institutions across multiple continents including Europe, South America, Asia Pacific, and Sub-Saharan Africa.